Vernal Keratoconjunctivitis Market to Witness Huge growth by 2028
Vernal Keratoconjunctivitis Market |
VKC (vertical
keratoconjunctivitis) is an allergic eye condition. It is a multifactorial
Th2-cell-mediated inflammatory ocular surface condition that typically affects
men, particularly youth. The most typical symptoms are intense itching,
burning, photophobia, and tears. Conjunctival hyperaemia, superficial
keratitis, and large papillae are the most prevalent symptoms. Vernal
keratoconjunctivitis is characterised by the overabundance of mast cells, Th2
cells, cytokines, eosinophils, adhesion molecules, chemokines, and cytokines.
Vernal keratoconjunctivitis is distinguished by limbal infiltration, corneal
involvement, fibroproliferative lesions, and conjunctival hyperemia. Vernal
keratoconjunctivitis is classified into three kinds depending on the predominant
anatomical location of the papillary reaction: mixed, palpebral, and limbal.
Increased medication approvals
allow for the provision of innovative treatment alternatives to patients, which
is expected to promote market growth over the projection period. For example,
Santen Pharmaceutical Co., Ltd. announced in June 2021 that the U.S. Food and
Drug Administration (FDA) authorised verkazia (Cyclosporine Ophthalmic
Emulsion, 0.1 percent) for the treatment of vernal keratoconjunctivitis (VKC)
in both children and adults. The worldwide vernal keratoconjunctivitis market's
key players are focused on pharmacological approvals, which are expected to
fuel market growth over the projected period.
According to Coherent Market Insights, The global Vernal
Keratoconjunctivitis Market is estimated to be valued at US$ 346.9 million in 2021 and is expected
to exhibit a CAGR of 3.6% during the forecast period (2021-2028).
The rising prevalence of vernal
keratoconjuctivitis in young people and children living in warm climates is
expected to drive market expansion over the projected period. Rising
occurrences of vernal keratoconjunctivitis, particularly in young people and
children living in warm climates, are expected to drive market expansion
throughout the projected period. The limbal variant of vernal
keratoconjunctivitis is particularly common among dark-skinned African and
Indian populations. In August 2021, for example, Western Europe occurrences
were 3.2 per 10,000, but Italy, a nation with a Mediterranean climate, had a
higher frequency ranging from 2.4 to 27.8 per 10,000.
Several doctors and patients
sought better treatment recommendations for COVID-19 pandemic patients with
vernal keratoconjunctivitis. The majority of patients and physicians followed
the recommendations of scientific bodies such as the Indian Journal of
Ophthalmology. Despite the fact that individuals require treatment, vernal
keratoconjuctivitis has not been prioritised recently in light of the multiple
issues related with the COVID-19 epidemic. Topical medications are the primary
line of therapy for most kinds of vernal keratoconjunctivitis, with topical
corticosteroids given in severe instances, even if the patient is at risk of
COVID-19.
There are no specific diagnostic
criteria for vernal keratoconjunctivitis, which is expected to limit market
growth throughout the projection period. The specific signs and symptoms of
vernal keratoconjunctivitis disease are utilised to make the diagnosis. Because
no precise diagnostic criteria have been identified, some mild or atypical
cases may go undiscovered.
Major Companies covered are- Santen, Novartis Pharmaceuticals,
Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics
Comments
Post a Comment